董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vicki Sato | 女 | Independent Director | 78 | 18.22万 | 31.29 | 2026-07-01 |
| John DeYoung | 男 | Independent Director | 63 | 未披露 | 未持股 | 2026-07-01 |
| Franz Humer | 男 | Lead Independent Director | 79 | 27.49万 | 54.81 | 2026-07-01 |
| Joshua Kazam | 男 | Director | 49 | 17.01万 | 59.43 | 2026-07-01 |
| Owen Witte | 男 | Independent Director | 76 | 19.31万 | 55.76 | 2026-07-01 |
| Deborah Messemer | 女 | Independent Director | 68 | 19.31万 | 43.46 | 2026-07-01 |
| Zachary Roberts | 男 | President and Chief Executive Officer and Director and Chief Medical Officer | 48 | 232.51万 | 119.49 | 2026-07-01 |
| Elizabeth Barrett | 女 | Independent Director | 64 | 18.31万 | 42.57 | 2026-07-01 |
| Stephen Mayo | 男 | Independent Director | 64 | 18.16万 | 35.93 | 2026-07-01 |
| Arie Belldegrun | 男 | Director and Executive Chair | 76 | 407.75万 | 1254.34 | 2026-07-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zachary Roberts | 男 | President and Chief Executive Officer and Director and Chief Medical Officer | 48 | 232.51万 | 119.49 | 2026-07-01 |
| Earl Douglas | 男 | Senior Vice President and General Counsel and Compliance Officer and Corporate Secretary | 63 | 未披露 | 未持股 | 2026-07-01 |
| Benjamin Beneski | 男 | Senior Vice President and Chief Technical Officer | 49 | 未披露 | 未持股 | 2026-07-01 |
| Geoffrey Parker | 男 | Executive Vice President, Chief Financial Officer | 61 | 228.14万 | 未持股 | 2026-07-01 |
| Arie Belldegrun | 男 | Director and Executive Chair | 76 | 407.75万 | 1254.34 | 2026-07-01 |
董事简历
中英对照 | 中文 | 英文- Vicki Sato
-
Vicki Sato自2020年2月以来一直担任我们的董事会成员。她于2006年9月至2017年7月担任哈佛商学院管理实践教授，并于2005年7月至2015年10月担任哈佛大学分子和细胞生物系教授。从2000年到2005年，她曾担任Vertex Pharmaceuticals公司（生物技术公司）的总裁。从1994年到2000年，她是Vertex研究与开发的高级副总裁，从1992年到1994年，她是研究的Vice President和首席科学官。在加入Vertex之前，佐藤博士曾担任BiogenInc.研究Vice President。佐藤博士自2006年起担任百时美施贵宝公司董事，自2014年起担任博格华纳公司董事，自2015年4月起担任Denali Therapeutics，Inc.董事，自2016年12月起担任VirBiotechnology，Inc.董事。佐藤博士曾于2013年8月至2019年12月担任SyrosPharmaceuticals，Inc.董事会成员。佐藤博士在Radcliffe College获得生物学学士学位，在Harvard University获得生物学硕士和博士学位。她在加州大学伯克利分校（University of California，Berkeley）和斯坦福医学中心（Stanford Medical Center）进行博士后工作。
Vicki Sato has served on our board of directors since February 2020. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. From 2000 to 2005 she served as president of Vertex Pharmaceuticals, Inc., a biotechnology company. From 1994 to 2000 she was the senior vice president of research and development at Vertex and from 1992 to 1994 she was the vice president of research and chief scientific officer. Prior to joining Vertex, Dr. Sato served as vice president of research at Biogen Inc. Dr. Sato has served on the board of directors at Bristol Myers Squibb Company since 2006 BorgWarner, Inc. since 2014 Denali Therapeutics, Inc. since April 2015 and Vir Biotechnology, Inc. since December 2016. Dr. Sato previously served on the board of Syros Pharmaceuticals, Inc. from August 2013 to December 2019. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center. - Vicki Sato自2020年2月以来一直担任我们的董事会成员。她于2006年9月至2017年7月担任哈佛商学院管理实践教授，并于2005年7月至2015年10月担任哈佛大学分子和细胞生物系教授。从2000年到2005年，她曾担任Vertex Pharmaceuticals公司（生物技术公司）的总裁。从1994年到2000年，她是Vertex研究与开发的高级副总裁，从1992年到1994年，她是研究的Vice President和首席科学官。在加入Vertex之前，佐藤博士曾担任BiogenInc.研究Vice President。佐藤博士自2006年起担任百时美施贵宝公司董事，自2014年起担任博格华纳公司董事，自2015年4月起担任Denali Therapeutics，Inc.董事，自2016年12月起担任VirBiotechnology，Inc.董事。佐藤博士曾于2013年8月至2019年12月担任SyrosPharmaceuticals，Inc.董事会成员。佐藤博士在Radcliffe College获得生物学学士学位，在Harvard University获得生物学硕士和博士学位。她在加州大学伯克利分校（University of California，Berkeley）和斯坦福医学中心（Stanford Medical Center）进行博士后工作。
- Vicki Sato has served on our board of directors since February 2020. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. From 2000 to 2005 she served as president of Vertex Pharmaceuticals, Inc., a biotechnology company. From 1994 to 2000 she was the senior vice president of research and development at Vertex and from 1992 to 1994 she was the vice president of research and chief scientific officer. Prior to joining Vertex, Dr. Sato served as vice president of research at Biogen Inc. Dr. Sato has served on the board of directors at Bristol Myers Squibb Company since 2006 BorgWarner, Inc. since 2014 Denali Therapeutics, Inc. since April 2015 and Vir Biotechnology, Inc. since December 2016. Dr. Sato previously served on the board of Syros Pharmaceuticals, Inc. from August 2013 to December 2019. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.
- John DeYoung
-
John DeYoung，自2018年4月起担任Allogene Therapeutics, Inc.董事会成员。DeYoung先生担任薪酬委员会和国际及业务发展监督委员会成员。DeYoung先生是辉瑞肿瘤业务部门的全球业务发展副总裁。他是辉瑞肿瘤学领导团队及其全球业务发展领导团队的成员。DeYoung先生于1991年加入辉瑞，曾在财务、市场营销、商业发展和业务发展等领域担任领导职务。DeYoung先生于1985年获得密歇根州立大学商学学士学位，并于1990年获得芝加哥大学MBA学位。
John DeYoung,has served as a member of Allogene Therapeutics, Inc. Board since April 2018. Mr. DeYoung serves as a member of the Compensation Committee and the International and Business Development Oversight Committee. Mr. DeYoung is Vice President of Worldwide Business Development for Pfizer's Oncology Business Unit. He is a member of Pfizer's Oncology Leadership Team and its Worldwide Business Development Leadership Team. Mr. DeYoung joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development and Business Development. Mr. DeYoung received his bachelor's degree in business from Michigan State University in 1985 and his MBA from the University of Chicago in 1990. - John DeYoung，自2018年4月起担任Allogene Therapeutics, Inc.董事会成员。DeYoung先生担任薪酬委员会和国际及业务发展监督委员会成员。DeYoung先生是辉瑞肿瘤业务部门的全球业务发展副总裁。他是辉瑞肿瘤学领导团队及其全球业务发展领导团队的成员。DeYoung先生于1991年加入辉瑞，曾在财务、市场营销、商业发展和业务发展等领域担任领导职务。DeYoung先生于1985年获得密歇根州立大学商学学士学位，并于1990年获得芝加哥大学MBA学位。
- John DeYoung,has served as a member of Allogene Therapeutics, Inc. Board since April 2018. Mr. DeYoung serves as a member of the Compensation Committee and the International and Business Development Oversight Committee. Mr. DeYoung is Vice President of Worldwide Business Development for Pfizer's Oncology Business Unit. He is a member of Pfizer's Oncology Leadership Team and its Worldwide Business Development Leadership Team. Mr. DeYoung joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development and Business Development. Mr. DeYoung received his bachelor's degree in business from Michigan State University in 1985 and his MBA from the University of Chicago in 1990.
- Franz Humer
-
Franz Humer，自2018年4月起担任Allogene Therapeutics, Inc.董事会成员。Humer博士目前担任LetterOne Holdings S.A.的董事会成员，并担任Kallyope，Inc.的董事会主席。此外，Humer博士担任国际失踪和受剥削儿童中心的董事会成员，并且是Humer基金会的主席。Humer博士此前曾于2020年10月至2023年1月担任私营研究阶段生物技术公司Neogene Therapeutics，Inc.的董事会主席，并于2015年9月至2017年10月担任Kite的董事会成员。他还曾于2012年至2018年期间担任花旗集团公司独立董事，于2002年至2014年期间担任Chugai Pharmaceuticals Ltd.（Japan）独立董事，并于2016年4月至2019年12月期间担任Arix Bioscience plc独立董事。他曾于2005年至2017年担任帝亚吉欧集团（Diageo plc）董事长。他曾于2016年5月至2017年12月担任全球网络安全上市公司WISeKey SA的董事会成员。此外，胡默博士曾于1996年至1998年担任F. Hoffmann-La Roche Ltd.的制药主管和首席运营官，此前曾于1998年至2001年担任罗氏集团的首席执行官，后于2001年至2008年担任主席和首席执行官。他担任罗氏集团（Roche Holding Ltd.）董事长的任期从2008年延长至2014年。在加入罗氏集团之前，他曾在葛兰素史克（Glaxo Holdings plc）董事会任职，负责研究、业务发展、制造、商业战略以及所有非美国业务长达13年。1973年，胡默博士加入先灵葆雅公司，在拉丁美洲和欧洲担任多个一般管理职位。胡默博士就读于因斯布鲁克大学，在那里他获得了法学博士学位，并就读于枫丹白露的INSEAD，在那里他获得了MBA学位。
Franz Humer,has served as a member of Allogene Therapeutics, Inc. Board since April 2018. Dr. Humer currently serves on the board of directors of LetterOne Holdings S.A. and as Chair of the board of directors of Kallyope, Inc. In addition, Dr. Humer serves on the board of directors of the International Centre for Missing and Exploited Children and is Chair of the Humer Foundation. Dr. Humer previously served as Chair of the board of directors of Neogene Therapeutics, Inc., a private research-stage biotechnology company, from October 2020 until January 2023 and as a member of the board of directors of Kite from September 2015 until October 2017. He also served as an independent director of Citigroup Inc. from 2012 until 2018, Chugai Pharmaceuticals Ltd. (Japan) from 2002 until 2014, and Arix Bioscience plc from April 2016 to December 2019. He served as Chair of Diageo plc from 2005 to 2017. He served as a member of the board of directors of WISeKey SA, a publicly traded global cybersecurity company, from May 2016 to December 2017. In addition, Dr. Humer served as Head of Pharmaceuticals and then as Chief Operating Officer of F. Hoffmann-La Roche Ltd. from 1996 to 1998, prior to serving as Chief Executive Officer of Roche Group from 1998 to 2001 and later as Chair and Chief Executive Officer from 2001 to 2008. His tenure as Chair of Roche Holding Ltd. extended from 2008 to 2014. Before joining Roche Group, he served on the board of Glaxo Holdings plc and was responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Dr. Humer joined Schering Plough Corporation where he held various General Management positions in Latin America and Europe. Dr. Humer attended the University of Innsbruck, where he obtained a Ph.D. in Law, and INSEAD in Fontainebleau, where he obtained an MBA. - Franz Humer，自2018年4月起担任Allogene Therapeutics, Inc.董事会成员。Humer博士目前担任LetterOne Holdings S.A.的董事会成员，并担任Kallyope，Inc.的董事会主席。此外，Humer博士担任国际失踪和受剥削儿童中心的董事会成员，并且是Humer基金会的主席。Humer博士此前曾于2020年10月至2023年1月担任私营研究阶段生物技术公司Neogene Therapeutics，Inc.的董事会主席，并于2015年9月至2017年10月担任Kite的董事会成员。他还曾于2012年至2018年期间担任花旗集团公司独立董事，于2002年至2014年期间担任Chugai Pharmaceuticals Ltd.（Japan）独立董事，并于2016年4月至2019年12月期间担任Arix Bioscience plc独立董事。他曾于2005年至2017年担任帝亚吉欧集团（Diageo plc）董事长。他曾于2016年5月至2017年12月担任全球网络安全上市公司WISeKey SA的董事会成员。此外，胡默博士曾于1996年至1998年担任F. Hoffmann-La Roche Ltd.的制药主管和首席运营官，此前曾于1998年至2001年担任罗氏集团的首席执行官，后于2001年至2008年担任主席和首席执行官。他担任罗氏集团（Roche Holding Ltd.）董事长的任期从2008年延长至2014年。在加入罗氏集团之前，他曾在葛兰素史克（Glaxo Holdings plc）董事会任职，负责研究、业务发展、制造、商业战略以及所有非美国业务长达13年。1973年，胡默博士加入先灵葆雅公司，在拉丁美洲和欧洲担任多个一般管理职位。胡默博士就读于因斯布鲁克大学，在那里他获得了法学博士学位，并就读于枫丹白露的INSEAD，在那里他获得了MBA学位。
- Franz Humer,has served as a member of Allogene Therapeutics, Inc. Board since April 2018. Dr. Humer currently serves on the board of directors of LetterOne Holdings S.A. and as Chair of the board of directors of Kallyope, Inc. In addition, Dr. Humer serves on the board of directors of the International Centre for Missing and Exploited Children and is Chair of the Humer Foundation. Dr. Humer previously served as Chair of the board of directors of Neogene Therapeutics, Inc., a private research-stage biotechnology company, from October 2020 until January 2023 and as a member of the board of directors of Kite from September 2015 until October 2017. He also served as an independent director of Citigroup Inc. from 2012 until 2018, Chugai Pharmaceuticals Ltd. (Japan) from 2002 until 2014, and Arix Bioscience plc from April 2016 to December 2019. He served as Chair of Diageo plc from 2005 to 2017. He served as a member of the board of directors of WISeKey SA, a publicly traded global cybersecurity company, from May 2016 to December 2017. In addition, Dr. Humer served as Head of Pharmaceuticals and then as Chief Operating Officer of F. Hoffmann-La Roche Ltd. from 1996 to 1998, prior to serving as Chief Executive Officer of Roche Group from 1998 to 2001 and later as Chair and Chief Executive Officer from 2001 to 2008. His tenure as Chair of Roche Holding Ltd. extended from 2008 to 2014. Before joining Roche Group, he served on the board of Glaxo Holdings plc and was responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Dr. Humer joined Schering Plough Corporation where he held various General Management positions in Latin America and Europe. Dr. Humer attended the University of Innsbruck, where he obtained a Ph.D. in Law, and INSEAD in Fontainebleau, where he obtained an MBA.
- Joshua Kazam
-
Joshua Kazam是我们的创始人之一，自2017年6月成立以来一直担任我们的董事会成员。Kazam先生是上市生物制药公司AllogeneTherapeutics，Inc.的联合创始人，于2017年11月至2018年6月担任其总裁，目前担任其董事会成员。他是Kite Pharma的创始人，并于2009年6月成立至2017年10月担任其董事会成员。2009年6月，Kazam先生联合创立了Two River Consulting，LLC，这是一家生命科学咨询和投资公司。Kazam先生自2017年11月起担任Vida Ventures，LLC的董事。他自2016年5月起担任Vision Path，Inc.的董事，自2016年11月起担任ByHeart，Inc.的董事，自2019年4月起担任Breakthrough Properties LLC的董事，自2020年2月起担任Flying Eagle AcquisitionCorp.的董事。Kazam先生自Iconovir Bio，Inc.于2018年8月成立以来一直担任其总裁兼董事会成员。Kazam先生曾于2019年1月至2020年4月担任Diamond Eagle AcquisitionCorp.董事，2005年5月至2019年5月担任CapricorTherapeutics，Inc.董事，2018年1月至2019年3月担任铂金Eagle AcquisitionCorp.董事。铂金Eagle AcquisitionCorp.、钻石Eagle AcquisitionCorp.和Flying Eagle AcquisitionCorp.是为与一个或多个企业进行业务合并而成立的空白支票公司。Kazam先生自2016年6月起担任沙漠之花基金会总裁。Kazam先生在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得创业管理学士学位，并且是沃顿商学院（Wharton School）本科执行委员会的成员。
Joshua Kazam,has served as a member of Allogene Therapeutics, Inc. Board since November 2017. Mr. Kazam served as Allogene Therapeutics, Inc. President from November 2017 until June 2018. He was a founder of Kite and served as a member of Kite's board of directors from Kite's inception in June 2009 until October 2017. In June 2009, Mr. Kazam co-founded Two River, LLC, a life-science company incubation and investment firm. Mr. Kazam is a co-founder and Director of Vida Ventures, and an advisor to Symbiotic Capital. Mr. Kazam has served on the board of Kronos Bio, Inc. since June 2017. He also serves on the boards of the following private companies: Vision Path, Inc. (d/b/a Hubble Contacts) since May 2016, ByHeart, Inc. since November 2016, Breakthrough Properties LLC and Breakthrough Services LLC since April 2019, and Baby Generation since January 2018. Mr. Kazam has also served on the boards of several blank check companies formed for the purpose of effecting a business combination with one or more businesses: Screaming Eagle Acquisition Corp. from January 2022 until May 2024, Tishman Speyer Innovation Corp. II from February 2021 until December 2022, TS Innovation Acquisitions Corp. from November 2020 until June 2021, Soaring Eagle Acquisition Corp. from February 2021 to September 2021, Flying Eagle Acquisition Corp. from February 2020 until December 2020, Diamond Eagle Acquisition Corp. from January 2019 until April 2020, and Platinum Eagle Acquisition Corp. from January 2018 to March 2019. Mr. Kazam has served as the President of Desert Flower Foundation since June 2016. Mr. Kazam received his bachelor's degree in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and is a Member of the Wharton School's Undergraduate Executive Board, and is a Penn Medicine Trustee. - Joshua Kazam是我们的创始人之一，自2017年6月成立以来一直担任我们的董事会成员。Kazam先生是上市生物制药公司AllogeneTherapeutics，Inc.的联合创始人，于2017年11月至2018年6月担任其总裁，目前担任其董事会成员。他是Kite Pharma的创始人，并于2009年6月成立至2017年10月担任其董事会成员。2009年6月，Kazam先生联合创立了Two River Consulting，LLC，这是一家生命科学咨询和投资公司。Kazam先生自2017年11月起担任Vida Ventures，LLC的董事。他自2016年5月起担任Vision Path，Inc.的董事，自2016年11月起担任ByHeart，Inc.的董事，自2019年4月起担任Breakthrough Properties LLC的董事，自2020年2月起担任Flying Eagle AcquisitionCorp.的董事。Kazam先生自Iconovir Bio，Inc.于2018年8月成立以来一直担任其总裁兼董事会成员。Kazam先生曾于2019年1月至2020年4月担任Diamond Eagle AcquisitionCorp.董事，2005年5月至2019年5月担任CapricorTherapeutics，Inc.董事，2018年1月至2019年3月担任铂金Eagle AcquisitionCorp.董事。铂金Eagle AcquisitionCorp.、钻石Eagle AcquisitionCorp.和Flying Eagle AcquisitionCorp.是为与一个或多个企业进行业务合并而成立的空白支票公司。Kazam先生自2016年6月起担任沙漠之花基金会总裁。Kazam先生在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得创业管理学士学位，并且是沃顿商学院（Wharton School）本科执行委员会的成员。
- Joshua Kazam,has served as a member of Allogene Therapeutics, Inc. Board since November 2017. Mr. Kazam served as Allogene Therapeutics, Inc. President from November 2017 until June 2018. He was a founder of Kite and served as a member of Kite's board of directors from Kite's inception in June 2009 until October 2017. In June 2009, Mr. Kazam co-founded Two River, LLC, a life-science company incubation and investment firm. Mr. Kazam is a co-founder and Director of Vida Ventures, and an advisor to Symbiotic Capital. Mr. Kazam has served on the board of Kronos Bio, Inc. since June 2017. He also serves on the boards of the following private companies: Vision Path, Inc. (d/b/a Hubble Contacts) since May 2016, ByHeart, Inc. since November 2016, Breakthrough Properties LLC and Breakthrough Services LLC since April 2019, and Baby Generation since January 2018. Mr. Kazam has also served on the boards of several blank check companies formed for the purpose of effecting a business combination with one or more businesses: Screaming Eagle Acquisition Corp. from January 2022 until May 2024, Tishman Speyer Innovation Corp. II from February 2021 until December 2022, TS Innovation Acquisitions Corp. from November 2020 until June 2021, Soaring Eagle Acquisition Corp. from February 2021 to September 2021, Flying Eagle Acquisition Corp. from February 2020 until December 2020, Diamond Eagle Acquisition Corp. from January 2019 until April 2020, and Platinum Eagle Acquisition Corp. from January 2018 to March 2019. Mr. Kazam has served as the President of Desert Flower Foundation since June 2016. Mr. Kazam received his bachelor's degree in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and is a Member of the Wharton School's Undergraduate Executive Board, and is a Penn Medicine Trustee.
- Owen Witte
-
Owen Witte，自2018年4月起担任Allogene Therapeutics, Inc.董事会成员。Witte博士此前曾于2017年3月至2017年10月担任Kite董事会成员。Witte博士于1980年加入加州大学洛杉矶分校，目前担任大学微生物学、免疫学和分子遗传学教授，加州大学洛杉矶分校David Saxon发育免疫学主席，此前曾担任Eli和Edythe Broad再生医学和干细胞研究中心主任。Witte博士被加州大学董事会任命为大学教授，这是一项为国际最高荣誉学者保留的荣誉。Witte博士是美国国家科学院、美国艺术与科学院和美国国家医学研究院的成员。Witte博士目前在多个编辑和顾问委员会任职。他此前曾担任美国癌症研究协会的董事会成员。他被奥巴马总统任命为总统癌症小组成员。Witte博士拥有康奈尔大学学士学位和斯坦福大学医学博士学位。他在麻省理工学院完成了博士后研究。
Owen Witte,has served as a member of Allogene Therapeutics, Inc. Board since April 2018. Dr. Witte previously served as a member of the board of directors of Kite from March 2017 until October 2017. Dr. Witte joined the UCLA faculty in 1980, where he is presently a University Professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology and previously served as the director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Dr. Witte was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Dr. Witte currently serves on several editorial and advisory boards. He previously served on the board of directors for the American Association for Cancer Research. He was appointed by President Obama to the President's Cancer Panel. Dr. Witte holds a bachelor's degree from Cornell University and an M.D. from Stanford University. He completed postdoctoral research at the Massachusetts Institute of Technology. - Owen Witte，自2018年4月起担任Allogene Therapeutics, Inc.董事会成员。Witte博士此前曾于2017年3月至2017年10月担任Kite董事会成员。Witte博士于1980年加入加州大学洛杉矶分校，目前担任大学微生物学、免疫学和分子遗传学教授，加州大学洛杉矶分校David Saxon发育免疫学主席，此前曾担任Eli和Edythe Broad再生医学和干细胞研究中心主任。Witte博士被加州大学董事会任命为大学教授，这是一项为国际最高荣誉学者保留的荣誉。Witte博士是美国国家科学院、美国艺术与科学院和美国国家医学研究院的成员。Witte博士目前在多个编辑和顾问委员会任职。他此前曾担任美国癌症研究协会的董事会成员。他被奥巴马总统任命为总统癌症小组成员。Witte博士拥有康奈尔大学学士学位和斯坦福大学医学博士学位。他在麻省理工学院完成了博士后研究。
- Owen Witte,has served as a member of Allogene Therapeutics, Inc. Board since April 2018. Dr. Witte previously served as a member of the board of directors of Kite from March 2017 until October 2017. Dr. Witte joined the UCLA faculty in 1980, where he is presently a University Professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology and previously served as the director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Dr. Witte was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Dr. Witte currently serves on several editorial and advisory boards. He previously served on the board of directors for the American Association for Cancer Research. He was appointed by President Obama to the President's Cancer Panel. Dr. Witte holds a bachelor's degree from Cornell University and an M.D. from Stanford University. He completed postdoctoral research at the Massachusetts Institute of Technology.
- Deborah Messemer
-
Deborah Messemer，自2018年9月起担任Allogene Therapeutics, Inc.董事会成员。Messemer女士自2022年1月起担任TPG Inc.的董事，自2019年1月起担任PayPal Holdings，Inc.的董事。Messemer女士是一名注册会计师，于1982年加入毕马威国际的美国成员公司毕马威会计师事务所（KPMG LLP，简称“毕马威”），并于1995年获准加入合伙企业。最近，她担任毕马威湾区和西北地区的管理合伙人，直到2018年9月退休。Messemer女士职业生涯的大部分时间都在毕马威的审计业务中度过，担任审计业务合作伙伴，为多个行业领域的公共和私人客户提供服务。除了运营和审计方面的签约职责，她在SEC文件、尽职调查、首次公开募股、并购以及财务报告内部控制方面拥有丰富的经验。Messemer女士获得了得克萨斯大学阿灵顿分校会计学学士学位。
Deborah Messemer,has served as a member of Allogene Therapeutics, Inc. Board since September 2018. Ms. Messemer has served as a director of TPG Inc. since January 2022 and PayPal Holdings, Inc. since January 2019. Ms. Messemer is a certified public accountant and joined KPMG LLP ("KPMG"), the U.S. member firm of KPMG International, in 1982 and was admitted into the partnership in 1995. Most recently, she served as the Managing Partner of KPMG's Bay Area and Northwest region until her retirement in September 2018. Ms. Messemer spent the majority of her career in KPMG's audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to her operational and audit signing responsibilities, she has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting. Ms. Messemer received a bachelor's degree in accounting from the University of Texas at Arlington. - Deborah Messemer，自2018年9月起担任Allogene Therapeutics, Inc.董事会成员。Messemer女士自2022年1月起担任TPG Inc.的董事，自2019年1月起担任PayPal Holdings，Inc.的董事。Messemer女士是一名注册会计师，于1982年加入毕马威国际的美国成员公司毕马威会计师事务所（KPMG LLP，简称“毕马威”），并于1995年获准加入合伙企业。最近，她担任毕马威湾区和西北地区的管理合伙人，直到2018年9月退休。Messemer女士职业生涯的大部分时间都在毕马威的审计业务中度过，担任审计业务合作伙伴，为多个行业领域的公共和私人客户提供服务。除了运营和审计方面的签约职责，她在SEC文件、尽职调查、首次公开募股、并购以及财务报告内部控制方面拥有丰富的经验。Messemer女士获得了得克萨斯大学阿灵顿分校会计学学士学位。
- Deborah Messemer,has served as a member of Allogene Therapeutics, Inc. Board since September 2018. Ms. Messemer has served as a director of TPG Inc. since January 2022 and PayPal Holdings, Inc. since January 2019. Ms. Messemer is a certified public accountant and joined KPMG LLP ("KPMG"), the U.S. member firm of KPMG International, in 1982 and was admitted into the partnership in 1995. Most recently, she served as the Managing Partner of KPMG's Bay Area and Northwest region until her retirement in September 2018. Ms. Messemer spent the majority of her career in KPMG's audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to her operational and audit signing responsibilities, she has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting. Ms. Messemer received a bachelor's degree in accounting from the University of Texas at Arlington.
- Zachary Roberts
-
Zachary Roberts自2020年3月起担任我们的首席医疗官。加入我们之前，他曾担任KitePharma，Inc./吉利德科学公司（Gilead Sciences）的多种职务，最近担任Vice President，负责临床开发（2018年2月至2019年5月）。在加入Kite之前，Roberts博士于2015年1月至2015年7月担任Amgen Oncology的临床研究医学总监。Roberts博士在麻省总医院（Massachusetts General Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了内科和血液学/肿瘤学的培训。他在University of Maryland，College Park获得微生物学和免疫学学士学位，在University of Maryland，Baltimore获得免疫学博士学位和硕士学位。
Zachary Roberts has served as our Chief Medical Officer since March 2020. Prior to joining us, he served in various roles for Kite Pharma, Inc./Gilead Sciences, most recently as Vice President, Clinical Development from February 2018 to May 2019. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his B.S. in microbiology and immunology from the University of Maryland, College Park and both his Ph.D. in immunology and his M.D from the University of Maryland, Baltimore. - Zachary Roberts自2020年3月起担任我们的首席医疗官。加入我们之前，他曾担任KitePharma，Inc./吉利德科学公司（Gilead Sciences）的多种职务，最近担任Vice President，负责临床开发（2018年2月至2019年5月）。在加入Kite之前，Roberts博士于2015年1月至2015年7月担任Amgen Oncology的临床研究医学总监。Roberts博士在麻省总医院（Massachusetts General Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了内科和血液学/肿瘤学的培训。他在University of Maryland，College Park获得微生物学和免疫学学士学位，在University of Maryland，Baltimore获得免疫学博士学位和硕士学位。
- Zachary Roberts has served as our Chief Medical Officer since March 2020. Prior to joining us, he served in various roles for Kite Pharma, Inc./Gilead Sciences, most recently as Vice President, Clinical Development from February 2018 to May 2019. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his B.S. in microbiology and immunology from the University of Maryland, College Park and both his Ph.D. in immunology and his M.D from the University of Maryland, Baltimore.
- Elizabeth Barrett
-
Elizabeth Barrett，在加入UroGen之前，Barrett女士自2018年2月起担任诺华肿瘤学首席执行官和诺华执行委员会成员。在加入诺华之前，Barrett女士曾在辉瑞公司担任过各种领导职务，最近担任肿瘤学全球总裁，在此之前，担任欧洲全球创新制药总裁、北美专业护理业务部总裁以及美国肿瘤学区域总裁。在加入辉瑞之前，Barrett女士是Cephalon Inc.的副总裁兼肿瘤事业部总经理。Barrett女士拥有圣约瑟夫大学工商管理-市场营销硕士学位和路易斯安那大学学士学位。Barrett女士目前还担任Sage Therapeutics, Inc.（自2019年起）和Allogene Therapeutics, Inc.（自2021年起）的董事会成员。
Elizabeth Barrett,Prior to joining UroGen, Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. Prior to Novartis, Ms. Barrett served at Pfizer Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology. Prior to Pfizer, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received an M.B.A. degree in Business Administration-Marketing from Saint Joseph's University and a B.S. from the University of Louisiana. Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics, Inc. (since 2019) and Allogene Therapeutics, Inc. (since 2021). - Elizabeth Barrett，在加入UroGen之前，Barrett女士自2018年2月起担任诺华肿瘤学首席执行官和诺华执行委员会成员。在加入诺华之前，Barrett女士曾在辉瑞公司担任过各种领导职务，最近担任肿瘤学全球总裁，在此之前，担任欧洲全球创新制药总裁、北美专业护理业务部总裁以及美国肿瘤学区域总裁。在加入辉瑞之前，Barrett女士是Cephalon Inc.的副总裁兼肿瘤事业部总经理。Barrett女士拥有圣约瑟夫大学工商管理-市场营销硕士学位和路易斯安那大学学士学位。Barrett女士目前还担任Sage Therapeutics, Inc.（自2019年起）和Allogene Therapeutics, Inc.（自2021年起）的董事会成员。
- Elizabeth Barrett,Prior to joining UroGen, Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. Prior to Novartis, Ms. Barrett served at Pfizer Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology. Prior to Pfizer, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received an M.B.A. degree in Business Administration-Marketing from Saint Joseph's University and a B.S. from the University of Louisiana. Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics, Inc. (since 2019) and Allogene Therapeutics, Inc. (since 2021).
- Stephen Mayo
-
Stephen Mayo，自2022年7月起担任Allogene Therapeutics, Inc.董事会成员。自2021年以来，他一直担任Sarepta Therapeutics, Inc.的董事会成员、研发和审计委员会成员，并担任董事会成员以及默克制药公司（均为上市公司）的审计和研究委员会成员。此外，他还在Vida Ventures的科学顾问委员会任职。他与人共同创立了Molecular Simulations Inc.（现为Biovia）、Protabit LLC和公共抗体工程公司Xencor, Inc.。Mayo博士目前是加州理工学院（Caltech）的Bren生物学和化学教授和Merkin研究所教授。他于1992年加入加州理工学院，1994年至2007年担任加州理工学院霍华德·休斯医学研究所研究员，2007年至2010年担任研究副教务长，2010年至2020年担任生物和生物工程部主席。梅奥博士因其在蛋白质设计领域的开创性贡献，于2004年被选入美国国家科学院。他曾于2010年至2014年担任美国科学促进协会的当选董事会成员，并于2013年至2018年担任美国国家科学基金会国家科学委员会的主席任命。Mayo博士拥有宾夕法尼亚州立大学化学学士学位和加州理工学院化学博士学位。他分别在加州大学伯克利分校和斯坦福大学医学院完成了化学和生物化学方面的博士后工作。
Stephen Mayo,has served as a member of Allogene Therapeutics, Inc. Board since July 2022. Since 2021, he has served as a member of the board of directors and as a member of the research and development and audit committees of Sarepta Therapeutics, Inc., and as a member of the board of directors and on the audit and research committees of Merck & Co., Inc., each a publicly traded company. In addition, he serves on the scientific advisory board of Vida Ventures. He co-founded Molecular Simulations Inc. (now Biovia), Protabit LLC and Xencor, Inc., a public antibody engineering company. Dr. Mayo is currently the Bren Professor of Biology and Chemistry and Merkin Institute Professor at California Institute of Technology (Caltech). He joined the Caltech faculty in 1992, was a Caltech-based Howard Hughes Medical Institute Investigator from 1994 to 2007, served as Vice Provost for Research from 2007 to 2010 and served as Chair of the Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo was elected to the National Academy of Sciences in 2004 for his pioneering contributions in the field of protein design. He served as an elected board member for the American Association for the Advancement of Science from 2010 to 2014 and as a presidential appointee on the National Science Foundation's National Science Board from 2013 to 2018. Dr. Mayo holds a B.S. in Chemistry from Pennsylvania State University and a Ph.D. in Chemistry from Caltech. He completed postdoctoral work at both UC Berkeley and Stanford University School of Medicine in chemistry and biochemistry, respectively. - Stephen Mayo，自2022年7月起担任Allogene Therapeutics, Inc.董事会成员。自2021年以来，他一直担任Sarepta Therapeutics, Inc.的董事会成员、研发和审计委员会成员，并担任董事会成员以及默克制药公司（均为上市公司）的审计和研究委员会成员。此外，他还在Vida Ventures的科学顾问委员会任职。他与人共同创立了Molecular Simulations Inc.（现为Biovia）、Protabit LLC和公共抗体工程公司Xencor, Inc.。Mayo博士目前是加州理工学院（Caltech）的Bren生物学和化学教授和Merkin研究所教授。他于1992年加入加州理工学院，1994年至2007年担任加州理工学院霍华德·休斯医学研究所研究员，2007年至2010年担任研究副教务长，2010年至2020年担任生物和生物工程部主席。梅奥博士因其在蛋白质设计领域的开创性贡献，于2004年被选入美国国家科学院。他曾于2010年至2014年担任美国科学促进协会的当选董事会成员，并于2013年至2018年担任美国国家科学基金会国家科学委员会的主席任命。Mayo博士拥有宾夕法尼亚州立大学化学学士学位和加州理工学院化学博士学位。他分别在加州大学伯克利分校和斯坦福大学医学院完成了化学和生物化学方面的博士后工作。
- Stephen Mayo,has served as a member of Allogene Therapeutics, Inc. Board since July 2022. Since 2021, he has served as a member of the board of directors and as a member of the research and development and audit committees of Sarepta Therapeutics, Inc., and as a member of the board of directors and on the audit and research committees of Merck & Co., Inc., each a publicly traded company. In addition, he serves on the scientific advisory board of Vida Ventures. He co-founded Molecular Simulations Inc. (now Biovia), Protabit LLC and Xencor, Inc., a public antibody engineering company. Dr. Mayo is currently the Bren Professor of Biology and Chemistry and Merkin Institute Professor at California Institute of Technology (Caltech). He joined the Caltech faculty in 1992, was a Caltech-based Howard Hughes Medical Institute Investigator from 1994 to 2007, served as Vice Provost for Research from 2007 to 2010 and served as Chair of the Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo was elected to the National Academy of Sciences in 2004 for his pioneering contributions in the field of protein design. He served as an elected board member for the American Association for the Advancement of Science from 2010 to 2014 and as a presidential appointee on the National Science Foundation's National Science Board from 2013 to 2018. Dr. Mayo holds a B.S. in Chemistry from Pennsylvania State University and a Ph.D. in Chemistry from Caltech. He completed postdoctoral work at both UC Berkeley and Stanford University School of Medicine in chemistry and biochemistry, respectively.
- Arie Belldegrun
-
Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
Arie Belldegrun,is a co-founder of Allogene and has served as Executive Chair of Allogene Therapeutics, Inc. Board since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. ("Kite") and as a director from June 2009 until October 2017. Dr. Belldegrun has served as Chair of UroGen since December 2012, and previously served as Chair of Kronos Bio, Inc., from June 2017 to June 2025. He was a director of Ginkgo Bioworks, Inc., from September 2021 to November 2024. Dr. Belldegrun has also served on the boards of several private companies, including Breakthrough Properties LLC and Breakthrough Services LLC, since April 2019, ByHeart, Inc., since October 2019, and as Co-Chairman of Symbiotic Capital since June 2023. Dr. Belldegrun has also served as Chairman of Bellco Capital LLC since 2004, as Chair and Partner of Two River Group since June 2009, and as Senior Managing Director of Vida Ventures, LLC since November 2017. He is certified by the American Board of Urology and is a Fellow of the American Association of Genitourinary Surgeons. Dr. Belldegrun is Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles ("UCLA"). Prior to joining UCLA in October 1988, he was a research fellow at NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven Rosenberg. Dr. Belldegrun received his M.D. from the Hebrew University Hadassah Medical School in Jerusalem before completing his postgraduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School. - Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
- Arie Belldegrun,is a co-founder of Allogene and has served as Executive Chair of Allogene Therapeutics, Inc. Board since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. ("Kite") and as a director from June 2009 until October 2017. Dr. Belldegrun has served as Chair of UroGen since December 2012, and previously served as Chair of Kronos Bio, Inc., from June 2017 to June 2025. He was a director of Ginkgo Bioworks, Inc., from September 2021 to November 2024. Dr. Belldegrun has also served on the boards of several private companies, including Breakthrough Properties LLC and Breakthrough Services LLC, since April 2019, ByHeart, Inc., since October 2019, and as Co-Chairman of Symbiotic Capital since June 2023. Dr. Belldegrun has also served as Chairman of Bellco Capital LLC since 2004, as Chair and Partner of Two River Group since June 2009, and as Senior Managing Director of Vida Ventures, LLC since November 2017. He is certified by the American Board of Urology and is a Fellow of the American Association of Genitourinary Surgeons. Dr. Belldegrun is Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles ("UCLA"). Prior to joining UCLA in October 1988, he was a research fellow at NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven Rosenberg. Dr. Belldegrun received his M.D. from the Hebrew University Hadassah Medical School in Jerusalem before completing his postgraduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School.
高管简历
中英对照 | 中文 | 英文- Zachary Roberts
Zachary Roberts自2020年3月起担任我们的首席医疗官。加入我们之前，他曾担任KitePharma，Inc./吉利德科学公司（Gilead Sciences）的多种职务，最近担任Vice President，负责临床开发（2018年2月至2019年5月）。在加入Kite之前，Roberts博士于2015年1月至2015年7月担任Amgen Oncology的临床研究医学总监。Roberts博士在麻省总医院（Massachusetts General Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了内科和血液学/肿瘤学的培训。他在University of Maryland，College Park获得微生物学和免疫学学士学位，在University of Maryland，Baltimore获得免疫学博士学位和硕士学位。
Zachary Roberts has served as our Chief Medical Officer since March 2020. Prior to joining us, he served in various roles for Kite Pharma, Inc./Gilead Sciences, most recently as Vice President, Clinical Development from February 2018 to May 2019. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his B.S. in microbiology and immunology from the University of Maryland, College Park and both his Ph.D. in immunology and his M.D from the University of Maryland, Baltimore.- Zachary Roberts自2020年3月起担任我们的首席医疗官。加入我们之前，他曾担任KitePharma，Inc./吉利德科学公司（Gilead Sciences）的多种职务，最近担任Vice President，负责临床开发（2018年2月至2019年5月）。在加入Kite之前，Roberts博士于2015年1月至2015年7月担任Amgen Oncology的临床研究医学总监。Roberts博士在麻省总医院（Massachusetts General Hospital）和Dana Farber癌症研究所（Dana Farber Cancer Institute）完成了内科和血液学/肿瘤学的培训。他在University of Maryland，College Park获得微生物学和免疫学学士学位，在University of Maryland，Baltimore获得免疫学博士学位和硕士学位。
- Zachary Roberts has served as our Chief Medical Officer since March 2020. Prior to joining us, he served in various roles for Kite Pharma, Inc./Gilead Sciences, most recently as Vice President, Clinical Development from February 2018 to May 2019. Prior to joining Kite, Dr. Roberts served as Clinical Research Medical Director for Amgen Oncology from January 2015 to July 2015. Dr. Roberts completed his training in internal medicine and hematology/oncology at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his B.S. in microbiology and immunology from the University of Maryland, College Park and both his Ph.D. in immunology and his M.D from the University of Maryland, Baltimore.
- Earl Douglas
Earl Douglas，自2023年8月起担任公司高级副总裁、总法律顾问和合规官，自2024年1月起担任Allogene Therapeutics, Inc.公司秘书。在加入Allogene之前，Douglas先生曾担任执行副总裁、Applied Molecular运输总法律顾问。在担任该职务之前，他曾在Kiverdi，Inc.担任同样的职务。他还曾担任副总裁，BioMimetic Therapeutics、Spinal Dynamics和OPX Biotechnologies的总法律顾问。他之前曾在Wilson Sonsini Goodrich & Rosati担任法律顾问，职业生涯早期曾在Weil，Gotshal & Manges担任助理。此外，Douglas先生目前担任Lynch Regenerative Medicine，LLC的董事会成员。他在麻省理工学院获得化学工程学学士学位，在哥伦比亚大学法学院获得法学博士学位。
Earl Douglas,has served as the Company's Senior Vice President, General Counsel and Compliance Officer since August 2023 and as Allogene Therapeutics, Inc. Corporate Secretary since January 2024. Before joining Allogene, Mr. Douglas served as Executive Vice President, General Counsel of Applied Molecular Transport. Prior to that role, he served in the same capacity for Kiverdi, Inc. He has also served as Vice President, General Counsel at BioMimetic Therapeutics, Spinal Dynamics, and OPX Biotechnologies. He previously served as Counsel with Wilson Sonsini Goodrich & Rosati, and earlier in his career practiced as an Associate with Weil, Gotshal & Manges. In addition, Mr. Douglas currently serves as a member of the board of directors of Lynch Regenerative Medicine, LLC. He earned his B.S. in chemical engineering from the Massachusetts Institute of Technology and his J.D. from Columbia University School of Law.- Earl Douglas，自2023年8月起担任公司高级副总裁、总法律顾问和合规官，自2024年1月起担任Allogene Therapeutics, Inc.公司秘书。在加入Allogene之前，Douglas先生曾担任执行副总裁、Applied Molecular运输总法律顾问。在担任该职务之前，他曾在Kiverdi，Inc.担任同样的职务。他还曾担任副总裁，BioMimetic Therapeutics、Spinal Dynamics和OPX Biotechnologies的总法律顾问。他之前曾在Wilson Sonsini Goodrich & Rosati担任法律顾问，职业生涯早期曾在Weil，Gotshal & Manges担任助理。此外，Douglas先生目前担任Lynch Regenerative Medicine，LLC的董事会成员。他在麻省理工学院获得化学工程学学士学位，在哥伦比亚大学法学院获得法学博士学位。
- Earl Douglas,has served as the Company's Senior Vice President, General Counsel and Compliance Officer since August 2023 and as Allogene Therapeutics, Inc. Corporate Secretary since January 2024. Before joining Allogene, Mr. Douglas served as Executive Vice President, General Counsel of Applied Molecular Transport. Prior to that role, he served in the same capacity for Kiverdi, Inc. He has also served as Vice President, General Counsel at BioMimetic Therapeutics, Spinal Dynamics, and OPX Biotechnologies. He previously served as Counsel with Wilson Sonsini Goodrich & Rosati, and earlier in his career practiced as an Associate with Weil, Gotshal & Manges. In addition, Mr. Douglas currently serves as a member of the board of directors of Lynch Regenerative Medicine, LLC. He earned his B.S. in chemical engineering from the Massachusetts Institute of Technology and his J.D. from Columbia University School of Law.
- Benjamin Beneski
Benjamin Beneski，自2025年3月起担任Allogene Therapeutics, Inc.高级副总裁兼首席技术官。Beneski先生于2019年加入Allogene，担任Allogene Therapeutics, Inc.执行董事和工厂经理，在那里他在Cell Forge 1的设计、建设和成功启动中发挥了关键作用，该公司拥有最先进的细胞治疗制造设施Allogene疗法。从那时起，Beneski先生担任了一系列越来越高级的职务，包括制造副总裁和产品开发和制造副总裁，在那里他领导了下一代平台的开发，有效地管理了内部和外部制造网络，并推动了支持IND提交和确保商业准备的关键举措。在加入Allogene之前，Beneski先生曾在多家生物技术公司担任高级制造职务，包括Vir Biotechnology和安进。他获得了史蒂文斯理工学院的化学工程学士学位和东北大学的MBA学位。
Benjamin Beneski,has served as Allogene Therapeutics, Inc. Senior Vice President and Chief Technical Officer since March 2025. Mr. Beneski joined Allogene in 2019 as Allogene Therapeutics, Inc. Executive Director and Plant Manager, where he played a pivotal role in the design, construction, and successful startup of Cell Forge 1, Allogene Therapeutics, Inc. state-of-the-art cell therapy manufacturing facility. Since then, Mr. Beneski has advanced through a series of increasingly senior roles, including Vice President of Manufacturing and Vice President of Product Development and Manufacturing where he led the development of next-generation platforms, effectively managed internal and external manufacturing networks, and drove key initiatives to support IND submissions and ensure commercial readiness. Prior to joining Allogene, Mr. Beneski held senior manufacturing roles at various biotechnology companies, including Vir Biotechnology and Amgen. He earned a B.S. in chemical engineering from Stevens Institute of Technology and an MBA from Northeastern University.- Benjamin Beneski，自2025年3月起担任Allogene Therapeutics, Inc.高级副总裁兼首席技术官。Beneski先生于2019年加入Allogene，担任Allogene Therapeutics, Inc.执行董事和工厂经理，在那里他在Cell Forge 1的设计、建设和成功启动中发挥了关键作用，该公司拥有最先进的细胞治疗制造设施Allogene疗法。从那时起，Beneski先生担任了一系列越来越高级的职务，包括制造副总裁和产品开发和制造副总裁，在那里他领导了下一代平台的开发，有效地管理了内部和外部制造网络，并推动了支持IND提交和确保商业准备的关键举措。在加入Allogene之前，Beneski先生曾在多家生物技术公司担任高级制造职务，包括Vir Biotechnology和安进。他获得了史蒂文斯理工学院的化学工程学士学位和东北大学的MBA学位。
- Benjamin Beneski,has served as Allogene Therapeutics, Inc. Senior Vice President and Chief Technical Officer since March 2025. Mr. Beneski joined Allogene in 2019 as Allogene Therapeutics, Inc. Executive Director and Plant Manager, where he played a pivotal role in the design, construction, and successful startup of Cell Forge 1, Allogene Therapeutics, Inc. state-of-the-art cell therapy manufacturing facility. Since then, Mr. Beneski has advanced through a series of increasingly senior roles, including Vice President of Manufacturing and Vice President of Product Development and Manufacturing where he led the development of next-generation platforms, effectively managed internal and external manufacturing networks, and drove key initiatives to support IND submissions and ensure commercial readiness. Prior to joining Allogene, Mr. Beneski held senior manufacturing roles at various biotechnology companies, including Vir Biotechnology and Amgen. He earned a B.S. in chemical engineering from Stevens Institute of Technology and an MBA from Northeastern University.
- Geoffrey Parker
Geoffrey Parker，自2023年10月起担任Allogene Therapeutics, Inc.执行副总裁、首席财务官。在加入Allogene Therapeutics, Inc.之前，Parker先生曾担任Tricida的首席运营官、首席财务官和Tricida, Inc.的执行副总裁在加入TERM3之前，Parker先生曾担任首席财务官的TERM0 Anacor Pharmaceuticals，Anacor制药的合伙人和董事总经理，在那里他领导了西海岸医疗保健投资银行集团。此外，Parker先生目前还担任Perrigo Company PLC的董事会成员。他获得了达特茅斯学院经济学和工程科学双专业的学士学位，以及斯坦福大学商学院的MBA学位。
Geoffrey Parker,has served as Allogene Therapeutics, Inc. Executive Vice President, Chief Financial Officer since October 2023. Prior to joining Allogene Therapeutics, Inc., Mr. Parker served as Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida, Inc. Prior to joining Tricida, Mr. Parker served as Chief Financial Officer of Anacor Pharmaceuticals, and served as a Partner and Managing Director at Goldman Sachs, where he led the West Coast Healthcare Investment Banking group. In addition, Mr. Parker currently serves as a member of the board of directors of Perrigo Company plc. He earned a B.A. with a double major in Economics and Engineering Sciences from Dartmouth College and an MBA from the Stanford Graduate School of Business.- Geoffrey Parker，自2023年10月起担任Allogene Therapeutics, Inc.执行副总裁、首席财务官。在加入Allogene Therapeutics, Inc.之前，Parker先生曾担任Tricida的首席运营官、首席财务官和Tricida, Inc.的执行副总裁在加入TERM3之前，Parker先生曾担任首席财务官的TERM0 Anacor Pharmaceuticals，Anacor制药的合伙人和董事总经理，在那里他领导了西海岸医疗保健投资银行集团。此外，Parker先生目前还担任Perrigo Company PLC的董事会成员。他获得了达特茅斯学院经济学和工程科学双专业的学士学位，以及斯坦福大学商学院的MBA学位。
- Geoffrey Parker,has served as Allogene Therapeutics, Inc. Executive Vice President, Chief Financial Officer since October 2023. Prior to joining Allogene Therapeutics, Inc., Mr. Parker served as Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida, Inc. Prior to joining Tricida, Mr. Parker served as Chief Financial Officer of Anacor Pharmaceuticals, and served as a Partner and Managing Director at Goldman Sachs, where he led the West Coast Healthcare Investment Banking group. In addition, Mr. Parker currently serves as a member of the board of directors of Perrigo Company plc. He earned a B.A. with a double major in Economics and Engineering Sciences from Dartmouth College and an MBA from the Stanford Graduate School of Business.
- Arie Belldegrun
Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
Arie Belldegrun,is a co-founder of Allogene and has served as Executive Chair of Allogene Therapeutics, Inc. Board since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. ("Kite") and as a director from June 2009 until October 2017. Dr. Belldegrun has served as Chair of UroGen since December 2012, and previously served as Chair of Kronos Bio, Inc., from June 2017 to June 2025. He was a director of Ginkgo Bioworks, Inc., from September 2021 to November 2024. Dr. Belldegrun has also served on the boards of several private companies, including Breakthrough Properties LLC and Breakthrough Services LLC, since April 2019, ByHeart, Inc., since October 2019, and as Co-Chairman of Symbiotic Capital since June 2023. Dr. Belldegrun has also served as Chairman of Bellco Capital LLC since 2004, as Chair and Partner of Two River Group since June 2009, and as Senior Managing Director of Vida Ventures, LLC since November 2017. He is certified by the American Board of Urology and is a Fellow of the American Association of Genitourinary Surgeons. Dr. Belldegrun is Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles ("UCLA"). Prior to joining UCLA in October 1988, he was a research fellow at NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven Rosenberg. Dr. Belldegrun received his M.D. from the Hebrew University Hadassah Medical School in Jerusalem before completing his postgraduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School.- Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
- Arie Belldegrun,is a co-founder of Allogene and has served as Executive Chair of Allogene Therapeutics, Inc. Board since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. ("Kite") and as a director from June 2009 until October 2017. Dr. Belldegrun has served as Chair of UroGen since December 2012, and previously served as Chair of Kronos Bio, Inc., from June 2017 to June 2025. He was a director of Ginkgo Bioworks, Inc., from September 2021 to November 2024. Dr. Belldegrun has also served on the boards of several private companies, including Breakthrough Properties LLC and Breakthrough Services LLC, since April 2019, ByHeart, Inc., since October 2019, and as Co-Chairman of Symbiotic Capital since June 2023. Dr. Belldegrun has also served as Chairman of Bellco Capital LLC since 2004, as Chair and Partner of Two River Group since June 2009, and as Senior Managing Director of Vida Ventures, LLC since November 2017. He is certified by the American Board of Urology and is a Fellow of the American Association of Genitourinary Surgeons. Dr. Belldegrun is Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles ("UCLA"). Prior to joining UCLA in October 1988, he was a research fellow at NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven Rosenberg. Dr. Belldegrun received his M.D. from the Hebrew University Hadassah Medical School in Jerusalem before completing his postgraduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School.